News
Novo Nordisk gets CHMP backing for oral GLP-1 agonist Rybelsus in its marketing battle with Eli Lilly, plus positive opinions for Bayer’s diabetes drug Nubeqa, Emergent’s cholera vaccine, and more ...
The results of the SOUL trial reveal that the Danish pharma's Rybelsus formulation of semaglutide reduced the risk of MACE (cardiovascular death, non-fatal myocardial infarction (MI), or stroke ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback